The RNA m6A Reader YTHDF1 Is Required for Acute Myeloid Leukemia Progression.

Yun-Guang Hong Zhi-Gang Yang Yan Chen Tian Liu Yuyuan Zheng Chun Zhou Guo-Cai Wu Yinhui Chen Juan Xia Zhi-Gang Yang Wenxin Liu Yi Zhao Jin Chen Xiangwei Gao Zhang-Hui Chen

Published in: Cancer research (2023)

The m6A reader YTHDF1 is required for progression of acute myelogenous leukemia and can be targeted with the FDA-approved drug tegaserod to suppress leukemia growth.

Keyphrases

acute myeloid leukemia
allogeneic hematopoietic stem cell transplantation
bone marrow
liver failure
drug induced
respiratory failure
cancer therapy
drug administration
adverse drug
nucleic acid
acute respiratory distress syndrome